HGH Fragment 176-191
Truncated dynamic fragment of growth hormone tailored for adipose analysis in obesity models.
Open HGH Fragment 176-191 in the 3D analyzerAnalytical specification
| Empirical formula | C72H117N21O22S2 |
|---|---|
| Molecular weight | 1716.9 g/mol |
| Isoelectric point (pI) | 4.45 |
| Assay purity (HPLC) | 99.55% |
| Retention time | 5.15 min |
| Peak area / height | 11400 / 920 |
| Reference batch | FR-2026-X88 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | R-E-E-D-D-P-S-F-F-C-F-R-C-R-D-N-S |
Research characteristics
Fat Burning
Induces direct cellular triglyceride exit
Sugar Regulation
Maintains stable glucose variables
Muscle Mass
Preserves amino stores during deficit
Experimental
Highly requested metabolic marker
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.